Literature DB >> 1727744

Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study.

S J Sontag1, B I Hirschowitz, S Holt, M G Robinson, J Behar, M M Berenson, A McCullough, A F Ippoliti, J E Richter, G Ahtaridis.   

Abstract

Two hundred thirty patients with reflux symptoms and endoscopically proven erosive esophagitis were enrolled from 15 U.S. centers into a randomized, double-blind, dose-ranging study comparing placebo with omeprazole, 20 or 40 mg given once daily in the morning. Esophagitis grade 2 was present in 44% of patients, grade 3 in 37% of patients, and grade 4 in 19% of patients. Endpoints, defined as complete relief of heartburn and complete esophageal mucosal healing, were assessed after 4 and 8 weeks of treatment. Both omeprazole doses were significantly superior to placebo in complete endoscopic healing. After 8 weeks of treatment, 73.5% of patients in the 20-mg omeprazole group and 74.7% in the 40-mg omeprazole group, compared with 14.0% in the placebo group, had complete healing of the esophageal mucosa. At the end of the study, complete relief of daytime heartburn was obtained in 79.5% of patients in the 20-mg omeprazole group, 81.6% in the 40-mg omeprazole group, and 37.2% in the placebo group (P less than or equal to 0.05). Complete relief of nighttime heartburn was noted by 79.5% of patients in the 20-mg omeprazole group, 85.1% in the 40-mg omeprazole group, and 34.9% in the placebo group (P less than or equal to 0.05). The median time to complete relief of daytime and nighttime heartburn occurred earlier in the 40-mg group than in the 20-mg group (9 vs. 17 days and 9 vs. 20 days, respectively); however, these differences were not statistically significant. Relief of acid regurgitation and dysphagia also occurred earlier in the 40-mg group. Omeprazole was well tolerated in this group of patients. No unexpected adverse experiences occurred. The results of this study confirm those of six multicenter, international trials in which omeprazole in doses of 20-60 mg provided a degree of esophageal mucosal healing and complete relief of reflux symptoms superior to any other medical treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727744     DOI: 10.1016/0016-5085(92)91790-b

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  36 in total

1.  What is heartburn worth? A cost-utility analysis of management strategies.

Authors:  G R Heudebert; R M Centor; J C Klapow; R Marks; L Johnson; C M Wilcox
Journal:  J Gen Intern Med       Date:  2000-03       Impact factor: 5.128

2.  A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis.

Authors:  Charles J Lightdale; Colleen Schmitt; Clara Hwang; Bernard Hamelin
Journal:  Dig Dis Sci       Date:  2006-06-14       Impact factor: 3.199

3.  A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.

Authors:  Colleen Schmitt; Charles J Lightdale; Clara Hwang; Bernard Hamelin
Journal:  Dig Dis Sci       Date:  2006-04-27       Impact factor: 3.199

4.  Long-term experience of treating 185 patients with gastroesophageal reflux disease (GERD) by anti-reflux surgery respecting the functional-morphological restoration of the esophagus.

Authors:  R Horstmann; C Classen; S Röttgermann; M Langer; D Palmes
Journal:  Langenbecks Arch Surg       Date:  2005-11-18       Impact factor: 3.445

5.  Community-acquired pneumonia and acid-suppressive drugs: position statement.

Authors: 
Journal:  Can J Gastroenterol       Date:  2006-02       Impact factor: 3.522

Review 6.  Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials.

Authors:  Nabil Sultan; Jose Nazareno; James Gregor
Journal:  Can J Gastroenterol       Date:  2008-09       Impact factor: 3.522

Review 7.  Single-isomer drugs: true therapeutic advances.

Authors:  Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

9.  Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model.

Authors:  Joseph Romagnuolo; Michael A Meier; Daniel C Sadowski
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

10.  Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.

Authors:  J Dent; N D Yeomans; M Mackinnon; W Reed; F M Narielvala; D J Hetzel; E Solcia; D J Shearman
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.